Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs

References

• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59:762–84.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69:964–75.
   Google Scholar
• Haroon N, Inman RD. Infectious complications of biological therapy. Curr Opin Rheumatol. 2009;21:397–403.
   PubMed Web of Science ®Google Scholar
• Saketkoo LA, Espinoza LR. Impact of biologic agents on infec-tious diseases. Infect Dis Clin N Am. 2006;20:931-61, viii.
   Google Scholar
• Mori S, Cho I, Sugimoto M. A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis. J Rheu-matol. 2010;37:1547–8.
   Google Scholar
• Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol. 2007;19:619–25.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49: S156–65.
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheu-matic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983–9.
   Google Scholar
• McMahon BJ. Recent advances in managing hepatitis B. F1000 Med Rep. 2010;2:11.
   PubMedGoogle Scholar
• Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408.
   PubMedGoogle Scholar
• Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007;37:705–12.
   Google Scholar
• Stine JG, Khokhar OS, Charalambopoulos J, Shanmugam VK, Lewis JH. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immuno-modulatory therapy. Arthritis Care Res (Hoboken). 2010;62: 704–11.
   Google Scholar
• Yazdany J, Calabrese L. Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines? Arthritis Care Res (Hoboken). 2010;62:585–9.
   Google Scholar
• Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hep-atitis B virus infection. J Hepatol. 2007;46:160–70.
   PubMed Web of Science ®Google Scholar
• Schmeltzer P, Sherman KE. Occult hepatitis B: clinical impli-cations and treatment decisions. Dig Dis Sci. 2010;55:3328–35.
   PubMed Web of Science ®Google Scholar
• Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479–86.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, et al. Possible reactivation of potential hepatitis B virus occult infec-tion by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol. 2010;37:346–50.
   PubMed Web of Science ®Google Scholar
• Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010; 62:749–54.
   PubMed Web of Science ®Google Scholar
• Charpin C, Guis S, Colson P, Borentain P, Maffei JP, Alcaraz P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11:R179.
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheo-doridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69:1352–5.
   Google Scholar
• Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21:16–23.
   PubMed Web of Science ®Google Scholar
• Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosup-pressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. (in press).
   Google Scholar
• Raftery G, Griffiths B, Kay L, Kane D. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology (Oxford). 2007;46:1381 (author reply 1381–2).
   Google Scholar
• Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface anti-gen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol. 2007;25:888–9.
   Google Scholar
• Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007;13:508–9.
   PubMed Web of Science ®Google Scholar
• Montiel PM, Solis JA, Chirinos JA, a Casis B, Sanchez F, Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008;28:718–20.
   Google Scholar
• Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G. Spondyloarthropathy and chronic B hepatitis Effect of anti-TNF therapy. Joint Bone Spine. 2009;76:308–11.
   PubMed Web of Science ®Google Scholar
• Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Afro P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the lit-erature. J Rheumatol. 2009;36:1188–94.
   PubMed Web of Science ®Google Scholar
• Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a lit-erature review and potential mechanisms of action. Clin Rheu-matol. 2010;29:1021–9.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guide-lines for clinical approach. J Gastroenterol Hepatol. 2006;21: 1366–71.
   Google Scholar
• Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Canilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–30.
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–14.
   PubMed Web of Science ®Google Scholar
• Gonzalez SA, Keeffe EB. Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2009;7: 1053–62.
   PubMed Web of Science ®Google Scholar
• Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52–6.
   PubMed Web of Science ®Google Scholar